SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-042601
Filing Date
2021-08-09
Accepted
2021-08-09 16:02:15
Documents
72
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apls-10q_20210630.htm   iXBRL 10-Q 3197919
2 EX-31.1 apls-ex311_7.htm EX-31.1 18438
3 EX-31.2 apls-ex312_10.htm EX-31.2 17555
4 EX-32.1 apls-ex321_6.htm EX-32.1 8559
5 EX-32.2 apls-ex322_9.htm EX-32.2 8573
  Complete submission text file 0001564590-21-042601.txt   9324553

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA apls-20210630.xsd EX-101.SCH 64923
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE apls-20210630_cal.xml EX-101.CAL 47797
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apls-20210630_def.xml EX-101.DEF 204169
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20210630_lab.xml EX-101.LAB 429460
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20210630_pre.xml EX-101.PRE 359158
11 EXTRACTED XBRL INSTANCE DOCUMENT apls-10q_20210630_htm.xml XML 1477082
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 211156369
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences